FLOW-AF: A Study to Evaluate the Ablacon Electrographic FLOW EGF Technology

  • days left to enroll
  • participants needed
  • sponsor
    Ablacon, Inc.
Updated on 24 January 2021
Patty Hevey
Primary Contact
Nemocnice Na Homolce Hospital (1.2 mi away) Contact
cardiac mapping


This study is to evaluate the Ablacon Electrographic Flow (EGF) algorithm technology (Ablamap Software).


The objective of this study is to evaluate the reliability of the Ablacon Electrographic Flow (EGF) algorithm technology (Ablamap Software) to identify atrial fibrillation sources and guide ablation therapy in patients with persistent atrial fibrillation.

Condition Atrial Fibrillation, Persistent, Atrial Fibrillation, Persistent, Atrial Fibrillation, Persistent
Treatment Ablamap Software
Clinical Study IdentifierNCT04473963
SponsorAblacon, Inc.
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Suitable candidate for intra-cardiac mapping and ablation of atrial arrhythmias
Above eighteen (18) years of age or of legal age to give informed consent specific to state and national law
Subjects with a history of documented symptomatic, persistent or longstanding persistent atrial fibrillation < 36 months
Subject agrees to comply with study procedures and be available (geographically stable) for follow-up visits for at least 12 months
Treatment of atrial fibrillation within the past 36 months with ablation therapy presenting with recurrent symptoms of AF

Exclusion Criteria

LA diameter > 5.5 cm
Left ventricular ejection fraction (LVEF) < 40%
Presence of intramural thrombus, tumor or abnormality that precludes vascular access, catheter introduction or manipulation
Coagulopathy, bleeding diathesis or suspected procoagulant state
Known allergies or intolerance to anticoagulant and antiplatelet therapies to be used in conjunction with the study or contrast sensitivity that cannot be adequately pre-treated prior to the ablation procedure
Positive pregnancy test results for female patients of childbearing potential or breast feeding
Acute or chronic medical condition that in the judgment of the investigator would increase risk to the patient or deem the patient inappropriate to participate in the study
Mitral valve stenosis and/or severe mitral regurgitation
Valvular atrial fibrillation
Prosthetic valves
History of MI within 3 months prior to procedure
Atrial septal defect (ASD) or left atrial appendage (LAA) closure device
Atrial fibrillation from a reversible cause (e.g., surgery, hyperthyroidism, sarcoidosis or pericarditis)
Life expectancy < 12 months based on medical history or the medical judgement of the investigator
Implantable cardioverter defibrillators (ICD), cardiac resynchronization therapy (CRT) leads or pacemaker implant procedure
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note